LOS ANGELES, Nov. 14, 2023 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2023, and provided a corporate update. Third Quarter…Read More
Armata Pharmaceuticals Inc Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
